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ABSTRACT
Background Jeune asphyxiating thoracic dystrophy
( JATD) is a rare, often lethal, recessively inherited
chondrodysplasia characterised by shortened ribs and
long bones, sometimes accompanied by polydactyly, and
renal, liver and retinal disease. Mutations in intraﬂagellar
transport (IFT) genes cause JATD, including the IFT
dynein-2 motor subunit gene DYNC2H1. Genetic
heterogeneity and the large DYNC2H1 gene size have
hindered JATD genetic diagnosis.
Aims and methods To determine the contribution to
JATD we screened DYNC2H1 in 71 JATD patients JATD
patients combining SNP mapping, Sanger sequencing
and exome sequencing.
Results and conclusions We detected 34 DYNC2H1
mutations in 29/71 (41%) patients from 19/57 families
(33%), showing it as a major cause of JATD especially in
Northern European patients. This included 13 early protein
termination mutations (nonsense/frameshift, deletion, splice
site) but no patients carried these in combination,
suggesting the human phenotype is at least partly
hypomorphic. In addition, 21 missense mutations were
distributed across DYNC2H1 and these showed some
clustering to functional domains, especially the ATP motor
domain. DYNC2H1 patients largely lacked signiﬁcant extra-
skeletal involvement, demonstrating an important
genotype–phenotype correlation in JATD. Signiﬁcant
variability exists in the course and severity of the thoracic
phenotype, both between affected siblings with identical
DYNC2H1 alleles and among individuals with different
alleles, which suggests the DYNC2H1 phenotype might be
subject to modiﬁer alleles, non-genetic or epigenetic factors.
Assessment of ﬁbroblasts from patients showed
accumulation of anterograde IFT proteins in the ciliary tips,
conﬁrming defects similar to patients with other retrograde
IFT machinery mutations, which may be of undervalued
potential for diagnostic purposes.
INTRODUCTION
Asphyxiating thoracic dystrophy or Jeune syndrome
( Jeune asphyxiating thoracic dystrophy ( JATD);
MIM 208500), ﬁrst described in 1955,1 is a rare
genetically heterogeneous disorder characterised by
skeletal anomalies, primarily shortened ribs and
limbs, brachydactyly and polydactyly. Constriction of
the thoracic cage is associated with recurrent respira-
tory infections in particular in neonates and infants,
and in 60% of cases with lethal respiratory distress.2
Up to 30% of JATD patients also develop end stage
renal disease,3 with hepatic ﬁbrosis and retinal
involvement reported less frequently.4 5 JATD is a
member of the family of skeletal ‘ciliopathies’, disor-
ders associated with dysfunction of primary cilia, clas-
siﬁed as one of the six short-rib polydactyly syndrome
(SRPS) disorders.6 7 JATD along with Ellis-van
Creveld syndrome is an SRPS compatible with life,
rather than one of the four lethal SRPS subtypes
(SRPS I–IV).7 In addition, JATD is both phenotypic-
ally as well as genetically related to Sensenbrenner
syndrome (Cranioectodermal dysplasia; MIM
218330)8 and Mainzer-Saldino syndrome (Conorenal
syndrome; MIM 266920).9
Mutations in several different genes cause JATD.
These genes, IFT80,10 TTC21B/IFT139,11 IFT140,9 12
WDR19/IFT1448 andDYNC2H113 all encode proteins
that participate in ciliary intraﬂagellar transport (IFT),
an evolutionarily conserved process which is essential
for ciliogenesis and governs a variety of important cell
signalling events that are key to normal human devel-
opment.14 15 In IFT, two protein complexes IFT-A and
IFT-B are bidirectionally transported in cilia by
molecular motors, along with essential ciliary
cargos.16 17 The IFT80 protein is part of the IFT-B par-
ticle that consists of at least 14 proteins, which in asso-
ciation with kinesin-2 motors drives anterograde
transport from the ciliary base to the tip while IFT139,
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IFT140 and IFT144 are all part of the IFT-A particle that consists of
six proteins and in association with the cytoplasmic IFT dynein-2/
1b motor drives retrograde transport from the ciliary tip to the
base.17–19 The other three IFT-A members, IFT122, IFT43 and
WDR35, are mutated in Sensenbrenner syndrome.20–22 Similarly,
IFT144 and IFT80 are also mutated in overlapping milder
syndromes and in more severe type III short-rib polydactyly.8 23
IFT140 mutations were recently described in Mainzer-Saldino syn-
drome patients, and a subset of JATD patients with early end stage
renal disease and frequent retinopathy.9 12 Besides DYNC2H1 deﬁ-
ciency underlying JATD, 13 mutations have also been reported in
patients with two of the severe short-rib polydactyly subtypes,
Majewski syndrome (SRPS type II; MIM 263520)24 25 and
Verma-Neumoff syndrome (SRPS type III; MIM 263510).13 26
One SRPS type II family carrying double heterozygous pathogenic
mutations in bothNEK1 andDYNC2H1 was also suggestive of pos-
sible digenic inheritance.24 25 NEK1 dysfunction affects ciliogenesis
and since the protein was localised to the basal body and within the
cilium, a role in IFTwas suggested.24 25
The DYNC2H1 protein, initially identiﬁed in sea urchin
embryos,27 is the central ATPase subunit of IFT dynein-2 complex,
the principle minus-end directed microtubule motor that drives
retrograde transport of the IFT-A particle to regulate tip-to-base
transport.15 28 29 DYNC2H1 has a typical dynein heavy chain
organisation (ﬁgure 1) similar to other heavy chain dyneins under-
lying primary ciliary dyskinesia and other developmental disor-
ders.34–39 DYNC2H1 knockdown in Caenorhabditis elegans and
mice results in short cilia with bulged tips,40 41 and Hedgehog sig-
nalling, an important signalling pathway that regulates bone devel-
opment, is disrupted in Dync2h1-deﬁcient mice as a result of
defective retrograde IFT.41 42 The IFT dynein-2 protein complex
is not yet fully deﬁned28 43 but besides homodimers of DYNC2H1
heavy chains,29 40 44 it likely contains the light intermediate chain
DYNC2LI145–48 and intermediate chain DYNC2I1.49 Dynein light
chains DYNLL1/LC850 and DYNLT1/TCTEX143 51 have also been
associated with the IFT dynein-2 complex.
Several factors have historically impeded genetic diagnosis in
SRPS such as JATD, including extensive underlying genetic hetero-
geneity, small family sizes due to perinatal lethality and recently the
large size of the DYNC2H1 gene (90 exons) which make diagnostic
analysis by Sanger sequencing expensive. Next generation sequen-
cing (NGS) approaches of exome sequencing and targeted ciliome
resequencing have more recently started to impact this ﬁeld.8 9 12
Here, we investigated the contribution of DYNC2H1 to JATD by
mutational analysis in 57 families (71 affected patients) from two
centres at UCL-ICH London and Radboud University Nijmegen
Medical Centre, using a combination of single nucleotide poly-
morphism (SNP)-based homozygosity mapping, exome NGS and
Sanger sequencing. We report a total of 34 mutations affecting
19/57 (33%) of families, and only two of these mutations have pre-
viously been associated with JATD. We show that DYNC2H1 is a
major cause of JATD, particularly affecting North Europeans,
causing a predominantly thoracic phenotype. We also show that
imaging of IFT in patient-derived cells potentially provides a useful
diagnostic tool. The study conﬁrms the potential of high through-
put NGS to effectively identify the molecular basis of rare genetic-
ally heterogeneous diseases such as JATD, and to provide
important new genotype–phenotype data that were previously very
difﬁcult to obtain.
METHODS
Patients
Inclusion criteria for the study were clinical and radiological
signs of JATD (short ribs/ narrow thorax, small ilia with
acetabular spurs, short long bones and brachydactyly), and add-
itional features such as renal disease, liver disease, retinopathy
and polydactyly if present. The UCL samples had also all been
excluded for IFT80 mutations. A total of 71 JATD patient
samples (61 UCL, 7 Nijmegen) fulﬁlling these criteria were pro-
cessed by exome sequencing, and three Nijmegen samples were
screened for DYNC2H1 mutations by Sanger sequencing. All
blood and skin biopsy samples were obtained with informed
consent according to the approved guidelines of the local ethics
committees and review boards.
SNP array and CNV analysis
Genotyping of 262 000 SNPs was performed using 250 K NspI
Gene Chip Arrays (Affymetrix) according to the manufacturer’s
instructions, with genotypes extracted using Genotyping
Console software (Affymetrix). PLINK52 was used homozygos-
ity mapping and Copy Number Analyzer from Affymetrix
GeneChip (CNAG) V.2 software53 for copy number variation
(CNV) detection. All ‘UCL’ preﬁx London samples were ana-
lysed for CNVs using the ExomeDepth Program.54
Whole exome sequencing
The exomes of patients JATD-1 and -2 were targeted with the
Agilent SureSelect kit (Agilent V.1, 38 Mb) and sequenced on a
quarter of a SOLiD four sequencing slide. Reads (50 bp frag-
ments) were aligned to the Hg18 reference genome using
Bioscope V.1.3, after which variants were called by the diBayes
programme. Sample JATD-3 was targeted with the SureSelect kit
(Agilent V.2, 50 Mb) and sequenced on a Life Technologies
5500XL instrument. Reads (50 bp fragments) were aligned to
Hg19 reference genome, followed by variant calling using
Lifescope V.2.1 software. London samples (preﬁxed ‘UCL’ in
table 1) were either processed as part of the UK10K project for
exome sequencing as previously described using the Agilent V.2
50 Mb All Exon kit56 or using the Nimblegen V.3 kit (Axeq
Technologies). Variants from all samples were annotated and
prioritised to identify pathogenic mutations as previously
described for Nijmegen samples8 22 and London samples.56
Inclusion criteria for variants consisted of being covered by at
least 10 sequence reads wherein the variant must be present in at
least 20% of the reads (variants detected in 20%–80% of the
sequence reads were considered heterozygous). Variants anno-
tated in dbSNP132, the 1000 Genomes project, the Seattle
exome database (http://www.evs.gs.washington.edu) or in our
inhouse databases with an allele frequency above 0.5% were
removed. An autosomal recessive inheritance model was applied
for gene identiﬁcation, with known JATD and SRPS genes manu-
ally analysed using the Integrative Genomics Viewer (http://www.
broadinstitute.org/igv/). Candidate pathogenic variants were vali-
dated and assessed for familial segregation by Sanger sequencing.
Sanger sequencing
All 90 DYNC2H1 (NM_001080463.1) exons not covered by
whole exome sequencing (WES) or where the 250K SNP array
indicated DYNC2H1 as a primary candidate disease gene were
analysed by Sanger sequencing. DYNC2H1 primer pairs used
have previously been published.13 PCR products were puriﬁed,
sequenced and analysed as previously described.56 57
Immunoﬂuorescent microscopy
Patient and control ﬁbroblasts obtained from skin biopsies
under signed informed consent were seeded on cover glasses
and grown for 24 h in Dulbecco’s Modiﬁed Eagle Medium
(DMEM) with 20% fetal calf serum (FCS), then serum starved
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in DMEM with 0.2% FCS for 48 h. Cells were stained with
antibodies against IFT88 (rabbit polyclonal, 1:100, kindly pro-
vided by G Pazour and rabbit polyclonal 1:200, 13967-1-AP
from Proteintech), IFT57 (rabbit polyclonal, 1:250, kindly pro-
vided by G Pazour), acetylated α-tubulin (mouse monoclonal,
1:1000, T6793 from Sigma Aldrich) and RPGRIP1L (guinea
pig polyclonal; SNC040, 1:500) as previously described.57
Secondary antibodies used were Goat-anti-Mouse Alexa ﬂuor
405, Goat-anti-Guinea pig 568 (both from Invitrogen, 1:500)
and Goat-anti-Rabbit Alexa ﬂuor 488 (Molecular Probes,
1:500). After staining, coverslips were mounted with a drop of
Vectashield (Vector Laboratories) and imaged on a Zeiss Axio
Imager Z1 ﬂuorescence microscope (Zeiss) with ApoTome
attachment. Images were processed using AxioVision (Zeiss),
Adobe Photoshop CS4 and Adobe Illustrator CS4 (Adobe
Systems). A minimum of 100 cells per sample was assessed for
cilia length and localisation of IFT proteins.
Web resources
▸ Online Mendelian Inheritance in Man (OMIM) (http://www.
ncbi.nlm.nih.gov/Omim)
▸ University of California, Santa Cruz (UCSC) Genome
Browser (http://www.genome.ucsc.edu)
▸ The Consensus CDS (CCDS) project (http://www.ncbi.nlm.
nih.gov/projects/CCDS/)
▸ PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/)
Figure 1 Mutations causing Jeune asphyxiating thoracic dystrophy ( JATD). (A) Linear structure of the 4314 residue human DYNC2H1 protein
showing the location of the 34 mutations described in this study in black, below the protein. Brackets indicate synonymous change associated with
a splice site mutation. All previously reported DYNC2H1 mutations are shown above the protein, associated with JATD13 (black), short-rib
polydactyly syndrome (SRPS II)24 25 (red) and SRPS III13 26 (orange). Conserved protein domains were taken from the consensus CDS entry for
NP_001073932.1. The DYNC2H1 protein domains contain the six AAA+ domains of the hexomeric ring-like ATP-hydrolysing motor domain,
AAA1-AAA6: AAA1 (amino acids 1651–1875), AAA2 (aa. 1938–2161), AAA3 (aa. 2251–2505), AAA4 (aa. 2617–2863), AAA5 (aa. 3244–3479) and
AAA6 (aa. 3697–3912). In addition, other domain-associated structures allow DYNC2H1 to function as a motor: a thin microtubule binding stalk
domain between AAA4 and AAA5 for attachment to microtubules (MT-binding stalk, aa. 2881–3227); an N-terminal tail (DHC_N1, aa. 234–676);
and a linker domain (DHC_N2, aa. 1120–1520) thought to change position in different nucleotide states to create the powerstroke for motility along
microtubules; plus a conserved C-terminal domain arranged on top of the ATPase ring (Dynein_heavy, aa. 3621–4311).30 31 (B) The predicted
human DYNC2H1 protein is shown modelled to the resolved crystal structure of the cytoplasmic dynein heavy chain of Dictyostelium discoideum
(DYHC_DICDI; PBD 3VKH)32 using Swiss-Model.33 Amino acid residues 1204–2969 could be modelled with conﬁdence; AAA1, blue; AAA2, lime
green; AAA3, red; AAA4, dark grey. The chain B of 3VKH used for the modelling is highlighted in light grey. (C) The location of the DYNC2H1
missense mutations that map to the regions of the protein that were possible to model by homology are shown in black. (D) The p.R2481Q
substitution missense mutation could create a new hydrogen bond between Q2481 and the conserved tyrosine (TYR) at position Y2477.
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Table 1 Clinical information for DYNC2H1 JATD patients
Family Patient Origin Sex
Age range of
patient
Related
parents Hands Feet Rib cage Limbs
Short stature/
height
percentile Skeleton anomaly
Liver, kidney, eye
features Remarks
JATD-1
(Case 4*)
II-2 Dutch M 20s No No polydactyly,
metacarpals and
phalanges
radiologically normal
No polydactyly Narrow, short,
broad ribs,
thorax;
surgically
corrected
Mild shortening
radius/ulna in
infancy
P50 Trident appearance of
acetabular margins;
handlebar clavicles
Thoracic scoliosis
(convex to right); no
renal or retinal
involvement
Chest pain during and
after exercise and
stress; hypovascular
pancreas lesion
JATD-2
(Case 5*)
II-1 Dutch M 20s No Short distal carpals
and distal phalanges
in infancy;
brachydactyly
No polydactyly, Narrow, short,
horizontal ribs
Short limbs in
infancy
P25–50 Short iliac bones with
spur-like protrusions;
handlebar clavicles
Thoracolumbal
scoliosis (convex to
left); no renal or
retinal involvement
Syndactyly of digits 2
and 3 (both feet);
hallux valgus (right),
short breath during
sport
JATD-3
(Case 6, 7*)
II-4 Dutch M Late teens Yes Possible
brachydactyly (not
pronounced); no
polydactyly
No polydactyly Small,
bell-shaped
thorax with
short, broad
ribs and short
sternum
Shortened limbs
in infancy
At the age of
12 years height
below the third
centile
Abnormal pelvic
configuration with
acetabular spiky
protrusions; elevated
clavicles
No renal or retinal
abnormalities
Respiratory distress
after birth, which
improved after hours
II-5 Dutch M Died 2nd
month
(respiratory
insufficiency)
No polydactyly No polydactyly Narrow thorax,
short ribs
Short limbs NA Trident appearance of
acetabular margins;
elevated clavicles
Signs of mild retinitis
pigmentosa, bile
duct proliferation
and portal tract
fibrosis, renal
mesangial
glomerular sclerosis
Severe respiratory
distress at birth; lung
hypoplasia with
interstitial fibrosis;
cardiac septum defect;
cerebral
ventriculomegaly
JATD-4
UCL47
UCL47.1 Dutch F 30s No Brachydactyly; no
polydactyly
Brachydactyly;
no polydactyly
Narrow Mild shortening P50–75 Acetabular spurs, small
ilia
Mildly disturbed liver
enzymes; normal
vision, normal renal
ultrasound
JATD-5
UCL61
UCL61.1 Dutch M Fetus No No polydactyly No polydactyly Extremely
narrow
Short arms and
short bowed
femur
NA (fetus) Acetabular spurs Large kidneys on
ultrasound in utero
JATD-6 II-1 Dutch M Under 10 No No polydactyly No polydactyly Narrow Mild shortening P10–25.
(height 109 cm
at 5 years
6 months)
Small ilea with
acetabular spurs;
brachydactyly, mild
rhizomelic shortening
(neonatally)
No renal or retinal
involvement
Hernia inguinalis;
exorotation of legs;
chest and leg pain
induced by exercise
JATD-7
UCL19
UCL19.1 Belgian NA Fetus No No polydactyly. Short
and broad hands,
short fingers; fixed
extension of the first
interphalangeal
joints
No polydactyly Very narrow,
tubular
Short long
bones with
irregular
metaphysis and
bony spikes at
the ends
NA Normal vertebrae. Short
ilia with typical medial
bony projection
Perimembranous VSD
JATD-8 UCL
63
UCL63.1 German F Under 10 No No polydactyly No polydactyly Narrow thorax,
short
horizontal ribs
Very mild
shortening
P50–75 Small ilia, acetabular
spurs
No renal disease,
liver disease or
retinopathy
Continued
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Table 1 Continued
Family Patient Origin Sex
Age range of
patient
Related
parents Hands Feet Rib cage Limbs
Short stature/
height
percentile Skeleton anomaly
Liver, kidney, eye
features Remarks
JATD-9 II-1 Polish F Under 5 Yes No polydactyly,
mildly rhizomelic
shortening of upper
limbs and large
hands
No polydactyly Very narrow,
pectus
carinatus
P90 Anterior of ribs ossified
with wide rounded
margins, phalanges
have cone-shaped
epiphysis, short shafts
of phalanges and
metacarpal bones.
∼2 years advanced
bone age
Normal abdominal
ultrasound, no signs
of retinal disease
Mild respiratory
problems after birth
high forehead, widely
spaced teeth
JATD-10
UCL15
UCL15.1 UK
Ashkenasi
NA Fetus No No polydactyly No polydactyly Narrow Short femur NA (fetus) Small ilia, typical
acetabular spursUCL15.2 NA Fetus NA (fetus)
UCL15.3 NA Fetus NA (fetus)
JATD-11
UCL90
UCL90.1 UK F Under 5 No No polydactyly No polydactyly Narrow,
asymmetric
shape
Mildly shortened
upper and lower
extremities in
early childhood
Slightly short
stature
Pelvis radiologically
compatible with JATD
No retinal, renal or
liver disease
Delayed motor
milestones (walking
with 2.5 years of age),
valgus deformity of the
feet
JATD-12
UCL48
UCL48.1 UK F Died as
neonate
No No polydactyly No polydactyly Narrow, severe
shortening of
ribs with
bulbous
anterior ends
Mild shortening
long bones,
slight bowing of
femurs. Mildly
shortened
tubular bones of
hands
Limbs <5th
centile at 20/
40, chest size
queried
Horizontal acetabular
roof with medial and
lateral spurs, narrow
sciatic notches and
short iliac wings—
trident pelvis
Long superiorly
placed clavicles. No
renal, retinal or liver
disease
Severe respiratory
distress at birth, died
within hours of birth
UCL48.2 M Fetus NA (fetus)
UCL48.3 F Fetus NA (fetus)
JATD-13
UCL39
UCL39.1 Caucasian
USA
M Under 10 (loss
of follow-up)
Yes NA NA Narrow NA (not
documented)
NA NA
JATD-14
UCL80
UCL80.1 Turkish M Died in 1st
year
(respiratory
failure)
Yes No polydactyly,
cone-shaped
epiphyses
No polydactyly Severely
narrowed
Short long
bones
<P3 in infancy Trident acetabulum,
acetabular spurs, small
ilia
Severe respiratory
distress
UCL80.2 F Died at
1.5 years
(pneumonia)
No polydactyly No polydactyly Mild narrowing Short long
bones
<P3 in infancy Frequent chest
infections; no renal
or retinal
involvement
Albinism
JATD-15
UCL58
UCL58.1 Turkish M Died at
1.5 years
(respiratory
failure)
Yes No polydactyly No polydactyly Tubular
bell-shaped
thorax
Mildly shortened
extremities
P3 at 1.5 years Dysplastic acetabulum Normal kidney
function (unilateral
renal pelvic ectasia
seems unrelated to
JATD), no liver
disease, no
retinopathy
Valgus deformity of the
feet, mild frontal
bossing, left sided
testis hydrocele, patent
ductus arteriosus
JATD-16
UCL81
UCL81.1 Turkish M Mid-teens Yes Unilateral postaxial
polydactyly
No polydactyly Narrow Mild shortening P97 at 9 years Trident acetabulum,
acetabular spurs;
handlebar clavicles
Elevated liver
enzymes since age
7 years; no renal or
retinal involvement
Unilateral atresia of
external ear meatus
and ear anomaly
Continued
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Table 1 Continued
Family Patient Origin Sex
Age range of
patient
Related
parents Hands Feet Rib cage Limbs
Short stature/
height
percentile Skeleton anomaly
Liver, kidney, eye
features Remarks
JATD-17
UCL95
UCL95.1 Turkish F Under 5 No No polydactyly No polydactyly Narrow Short limbs in
early childhood
P3–10 at
3 years
Pelvis and thorax
radiologically
compatible with JATD
Normal renal
function and
ultrasound, no
retinitis pigmentosa,
normal liver function
Short neck, elevated
claviculae
UCL95.2 M Died at first
day of life
(respiratory
failure)
Narrow Short limbs NA No signs of renal,
retinal or liver
disease
UCL95.3 F Fetus Short ribs Short extremities NA NA
JATD-18
UCL62
UCL62.1 Turkish–
Kurdish
M Under 5 No No polydactyly No polydactyly Severely
narrow
Pelvis and thorax
radiologically
compatible with JATD
No renal or retinal
disease
Oesophageal atresia
UCL62.2 Under 5 No polydactyly,
broad hands, short
fingers
No polydactyly Milder
narrowing
Broad hands
and toes,
slightly short
fingers
NA
JATD-19
UCL109
UCL109.1 UK
Yemen–
Somali
M Under 5 No No polydactyly No polydactyly Severely
narrowed
Height NA, not
obviously
below average
Pelvis and thorax
radiologically
compatible with JATD
No renal or retinal
involvement
Severe respiratory
distress, tracheostoma,
currently on home
ventilation at night
UCL109.2 M Under 5 Narrow No renal or retinal
involvement
Very mild respiratory
symptoms
*Patient previously described.55 Ages approximated to protect patient privacy. Clinical details relate to information taken at ascertainment or at most recent review, indicated in ‘age range’ column. Retinal disease was excluded in most patients with
fundoscopy.
JATD, Jeune asphyxiating thoracic dystrophy; IFTB, intraflagellar transport complex B; NA, not available; UCL, University College London; VSD, ventricular septum defect.
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▸ Copy Number Analyzer for Affymetrix GeneChip (http://
www.genome.umin.jp/)
▸ GraphPad, Quick Calcs (http://www.graphpad.com/quickcalcs/
chisquared2.cfm)
▸ Polyphen2 (http://genetics.bwh.harvard.edu/pph2/)
▸ Mutationtaster (http://www.mutationtaster.org/)
▸ Sorting intolerant from tolerant (SIFT) (http://sift.jcvi.org/)
▸ Genomic evolutionary rate proﬁling (GERP) (http://mendel.
stanford.edu/SidowLab/downloads/gerp)
▸ PhyloP (http://genome.ucsc.edu)
▸ Alamut (http://www.interactive-biosoftware.com/software/
alamut/features)
RESULTS
DYNC2H1 mutations are a major genetic cause of JATD
In total, we detected causative (biallelic) DYNC2H1 mutations
in 29/71 patients (41%) from 19/57 families (33%) with JATD.
The patient’s clinical information is provided in table 1, and the
detected mutations are summarised in table 2. We validated all
DYNC2H1 variants identiﬁed by exome sequencing with Sanger
sequencing, and tested whether the variants segregated with
disease in all families. In all cases the segregation pattern was
consistent with a recessive inheritance pattern (see online
supplementary ﬁgure S1), and none of the mutations were iden-
tiﬁed in 500 inhouse control exomes with an allele frequency
>0.005. Although the majority of these families were solved
directly through exome sequencing, DYNC2H1 was initially not
targeted in the Agilent V.1 (38 Mb) exome kit. Still, sufﬁcient
coverage was generated for 30% of the DYNC2H1 exons due to
the capture by enrichment probes targeting homologous regions
(ie, coverage was generated for regions that were not contained
in the exome design). Somewhat surprisingly, this resulted in the
detection of a heterozygous p.D3015G variant (table 2) in
JATD-1 and -2, through capturing the correct regions despite
their not being targeted. This mutation was validated by Sanger
sequencing using a locus speciﬁc and relatively long (450 bp)
PCR amplicon.
With the improved Agilent V.2 50 Mb kits, the entire
DYNC2H1 gene was targeted, and this signiﬁcantly improved
coverage to approximately 90% of all coding exons, using a
‘calling-on-target’ strategy. A comparison of coverage across the
DYNC2H1 gene for the different exome sequencing kits used
for screening is shown in online supplementary ﬁgure S2. In
parallel, targeted Sanger sequencing of the initially non-covered
DYNC2H1 exons was performed, which revealed mutations pre-
viously missed by WES in patients JATD-1, -2 and -10 (table 2).
These data show that WES, despite its revolutionary improve-
ments for gene sequencing, also poses challenges for mutation
identiﬁcation in research and DNA diagnostic settings.
All Nijmegen samples were analysed using SNP microarray
analysis prior to exome sequencing and this had excluded larger
CNVs in all patients apart from one deletion of exons 81–83
identiﬁed in patient JATD-6, who additionally carried two het-
erozygous missense changes identiﬁed by Sanger sequencing. In
comparison with Sanger sequencing, NGS data also offers the
opportunity to identify CNVs; London exomes underwent
CNV analysis using ExomeDepth54 and we identiﬁed a large
heterozygous deletion encompassing the last three exons of
DYNC2H1 exons in patient JATD-7, in addition to a missense
mutation detected by conventional WES analysis (see online
supplementary ﬁgures S2 and S3, table 2). Finally, we also iden-
tiﬁed mutations in the consanguineous family JATD-9 through
SNP array-based homozygosity mapping followed by targeted
Sanger sequencing.
Mutations causing nonsense, frameshift and essential splice site
changes were judged to be disease causing, and the identiﬁed var-
iants were also assessed for their pathogenic potential using ﬁve
different bioinformatics tools (see online supplementary table S1).
These incorporate evolutionary conservation of residues to gauge
their functional importance; corresponding multispecies align-
ment of all variants is shown in online supplementary ﬁgure S4.
While most mutations are clearly predicted to impair protein func-
tion by most of the tools used, three missense alleles gave more
equivocal results: p.R2481Q, p.M2227V and p.M1379V.
p.R2481Q is rather poorly predicted for pathogenicity; however,
there is high evolutionary conservation at this residue (see online
supplementary ﬁgure S4) and it is carried in JATD-3 in combin-
ation with a nonsense change. The effect of p.R2481Q was mod-
elled onto the predicted DYNC2H1 protein, showing that
substitution of a glutamate at this residue potentially signiﬁcantly
affects the tertiary structure, leading to a new hydrogen bond
between Q2481 and the conserved tyrosine at position Y2477
(ﬁgure 1C). p.M2227V in JATD-17 was found as a homozygous
change and p.M1379V in JATD-11 as a heterozygous change.
Protein modelling of these substitutions on the tertiary model of
DYNC2H1 did this not reveal any suggested mechanism for their
pathogenic effect (data not shown). Both are predicted as benign
by Polyphen-2 but as deleterious by SIFT and predicted to create
new splice donor sites by Mutation Taster; moreover, the second
allele in JATD-17 is a nonsense allele (p.L4177Ffs*29) and in
JATD-11 is in an early and essential splice site predicting abolish-
ment of the exon 1 splice donor.
The heterozygous p.P2797_L2799del in JATD-15 creates an
inframe loss of three amino acids which cannot be scored by the
software, but these residues proline-alanine-leucine (PAL) are highly
conserved and thus their loss is likely to be functionally important
(see online supplementary ﬁgure S4). Finally, variants in JATD-16
(c.7437+3A>G) and JATD-18 (c.2346−5T>G) are the only splice
site mutations not affecting a 100% conserved splice site nucleo-
tides. However, both still affect a highly conserved splice site
nucleotide, are predicted by Mutation Taster to cause splice defects,
and also have signiﬁcant GERP, SIFT and PhyloP conservation
scores; moreover, the second variant in both cases is strongly pre-
dicted to be pathogenic. Patient material was not available from
either family, preventing an assessment of the relevance of these var-
iations at the RNA level.
DYNC2H1 mutational spectrum in JATD
The DYNC2H1 mutation distribution is summarised in table 2
and ﬁgure 1. A total of 34 likely pathogenic DYNC2H1 variants
were identiﬁed as likely to be causal in 29 patients from 19 fam-
ilies. These comprised six splice site mutations and seven non-
sense/deletion/frameshift ‘null’ mutations that were never seen
in combination together, in addition to 21 missense changes
(ﬁgure 1A). Overall, 30/34 mutations were private, while three
have been previously reported: p.D3015G and p.I1240Teach in
one JATD patient13 and p.R330C in an SRPS II patient.24 The
p.D3015G mutation seems to occur only in North European
patients so far, and could represent a founder allele in this
population. p.Glu436*, not previously reported, was present in
two unrelated Dutch families JATD-1 and -4.
Biallelic mutations were identiﬁed in 16/19 families, but more
than two were identiﬁed in JATD-5, -6 and -17. The JATD-5 allele
p.L1228I is a polymorphism not annotated as pathogenic
(rs189806840), and therefore is the most likely to be excluded as a
disease cause. JATD-6 carried the common mutation p.D3015G,
and a large deletion p.G3891_Q4020; the third variant is a het-
erozygous missense change p. R3813C. Together with a well-
Schmidts M, et al. J Med Genet 2013;50:309–323. doi:10.1136/jmedgenet-2012-101284 315
Developmental defects
Table 2 Identified DYNC2H1 mutations
Family Nucleotide change Mutation Var Location ID method Remarks Functional validation
JATD-1 c. 90443A>G p.D3015G Het Exon 57 WES (Agilent 38 Mb) rs137853027† ∼50% of cilia have bulged tips filled with IFT-B proteins, normal cilia length.
rs137853027: minor allele frequency (EVS) 3 in 11957 alleles (0.00026 or 0.026%)c. 1306G>T p.E436* Het Exon 9 SS
JATD-2 c.9044A>G p.D3015G Het Exon 57 WES (Agilent 38 Mb) rs137853027† ∼50% of cilia have bulged tips filled with IFT-B proteins, normal cilia length.
rs137853027: Minor allele frequency (EVS) 3 in 11957 alleles (0.00026 or 0.026%)c.3459-1G>A Exon 24 splice acceptor Het Intron 23 SS
JATD-3 c.9817C>T p.E3273* Het Exon 62 WES (Agilent 50 Mb) ∼ 15% of cilia have bulged tips filled with IFTB proteins, normal cilia length
c.7442G>A p.R2481Q Het Exon 46
JATD-4 c.1306G>T p.E436* Het Exon 9 WES (Agilent 50 Mb)
c.8457A>G p.I2819M Het Exon 53
JATD-5 c.3682C>A p.L1228I Het Exon 25 WES (Nimblegen V.3) rs189806840 (dbSNP) rs137853027: Minor allele frequency (EVS) 16 in 11820 alleles (0.00135 or 0.135%)
c.7663G>A p.V2555M Het Exon 47
c.7718A>G p.Y2573C Het Exon 48
JATD-6 14kb deletion
(g.103191405-103204921)
p.G3891_Q4020del Het Del exons 81–83 SNP microarray CNV analysis
and SS
c.9044A>G p.D3015G Het Exon 57 SS rs137853027† rs137853027: minor allele frequency (EVS) 3 in 11957 alleles (0.00026 or 0.026%)
c.11437C>T p.R3813C Het Exon 79 SS
JATD-7 c.10163C>T p.P3388L Het Exon 67 WES (Agilent 50 Mb)
c.12480_13556del
(g.103325916-103350592)
p.N4160_Q4314del Het Del exons 87–90 Exome CNV analysis
JATD-8 c.3719T>C p.I1240T Het Exon 25 WES (Agilent 50 Mb) rs137853028† rs137853028: not seen in EVS
c.12716T>G p.L4239R Het Exon 89
JATD-9 c. 11560T>G p.W3854G Hom Exon 80 HZ mapping (250 K) then SS
JATD-10 c.6910G>A p.A2304T Het Exon 43 SS 3 affected sibs
c.8389_8397delCCAGCTTTG p.P2797_L2799del Het Exon 52 WES (Agilent 50 Mb)
JATD-11 c.195G>T p.T65T Het Exon 1 splice donor WES (Agilent 50 Mb)
c.4135A>G p.M1379V Het Exon 27
JATD-12 c.312_313delTA p.P104PfsX*2 Het Exon 2 WES (Agilent 50 Mb) 3 affected sibs
c.5972T>A p.M1991K Het Exon 38
JATD-13 c.4325G>A p.G1442D Het Exon 28 WES (Agilent 50 Mb)
c.1953G>A p.K651K Het Exon 13 splice donor
JATD-14 c.988C>T p.R330C Hom Exon 6 WES (Agilent 50 Mb) 2 affected sibs
JATD-15 c. 7594C>T p.R2532W Hom Exon 47 WES (Agilent 50 Mb)
JATD-16 c.7437+3A>G Exon 45 splice donor Het Intron 45 WES (Agilent 50 MB) Normal cilia length
c.7539A>T p.G2513G Het Exon 46 splice donor
JATD-17 c.6679A>G p.M2227V Hom Exon 42 WES (Agilent 50 Mb)
c.12538delC p.L4177Ffs*29 Het Exon 87
JATD-18 c.2346-5T>G Exon 17 splice acceptor Het Intron 16 WES (Agilent 50 Mb) 2 affected sibs
c.7085A>G p.N2362S Het Exon 43
JATD-19 c.7919T>C p.I2640T Het Exon 49 WES (Agilent 50 Mb) 2 affected sibs
c.2612T>C p.L871P Het Exon 18
†Annotated as pathogenic in dbSNP due to previous publication.13 EVS, NHLBI Exome Variant Server (http://evs.gs.washington.edu/EVS/). Functional validation refers to analysis in ciliated patient-derived fibroblasts. Nucleotides numbered according to
Ensembl transcript DYNC2H1-005 ENST00000398093.
WES, whole exome sequencing with Agilent 38 or 50 Mb kit or Nimblegen V.3 kit; SS, Sanger sequencing; HZ mapping, SNP array-based homozygosity mapping.
CNV, copy number variation; IFT, intraflagellar transport; JATD, Jeune asphyxiating thoracic dystrophy; SNP, single nucleotide polymorphism.
*Indicates a stop codon insertion.
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supported heterozygous frameshift mutation p.L4177Ffs*29,
JATD-17.1 carries a homozygous missense p. M2227V.
The 21 missense mutations were distributed along the length
of DYNC2H1 (ﬁgure 1A); however, some clustering was evident
since the majority (16/21) were localised to deﬁned functional
heavy chain protein domains, mainly the AAA+ motor domain,
rather than to protein areas in between deﬁned domains
(ﬁgure 1A). This clustering focused around the AAA3 and AAA4
domains which contained 8/21 missense changes (38%), with
fewer in AAA2, AAA5 and AAA6, and none present in AAA1.
Fisher’s exact test was used to evaluate the missense mutation dis-
tribution, comparing windows of 100 subsequent amino acids
along the DYNC2H1 protein. This revealed a statistically signiﬁ-
cant enrichment (p<0.01) of mutations between the AAA3 and
AAA4 domains (see online supplementary ﬁgure S5), although
after correcting for multiple hypothesis testing using False
Discovery Rate this enrichment is no longer statistically signiﬁ-
cant (see online supplementary ﬁgure S5). We compared the
DYNC2H1 mutation distribution with that of DNAH5 which is
mutated in a different ciliopathy, primary ciliary dyskinesia,
where mutations are considered to be highly deleterious in their
effect leading to complete loss of the DNAH5 protein.35 58–60
The distribution of DNAH5 missense mutations mirrored that of
DYNC2H1 since they also clustered to the functional domains of
DNAH5 (p<0.01), and similarly this signiﬁcance was lost after
False Discovery Rate multiple hypothesis testing correction (see
online supplementary ﬁgure S5).
The total number of DYNC2H1missense mutations analysed are
too small to make robust conclusions; however, this trend in the
ﬁndings warrants further investigations to shed new light on the
functional role of DYNC2H1 in JATD. Figure 1C illustrates this
tendency of DYNC2H1 missense mutations to localise within the
known functional domains in a 3D model of the protein, including
the AAA domains. It was possible to determine the location of 14
of the missense changes within the tertiary structure of the protein
(ﬁgure 1C) by homology modelling to the most advanced crystal
structure of the protein, which has been determined in
Dictyostelium discoideum (ﬁgure 1B).32
Variable thoracic phenotype severity in JATD patients with
DYNC2H1 mutations
DYNC2H1 mutations in our genetically deﬁned JATD cohort pri-
marily result in defects of the skeleton. The clinical course was
dominated by abnormal bone development (ﬁgure 2A–E), univer-
sally affecting the thorax cage due to a reduced rib length. Typical
handlebar clavicles were observed (see online supplementary ﬁgure
S6). The scoliosis evident in JATD-1 and -2 could be part of the
primary skeletal phenotype; this should thus be regularly moni-
tored (ﬁgure 2J). Several patients have brachydactyly with cone-
shaped epiphyses but this was not universal; for example, brachy-
dactyly and cone-shaped epiphyses were absent in JATD-1 and -16
(see online supplementary ﬁgure S6). Since cone-shaped epiphyses
tend to only be visible after the ﬁrst year of life, the age at observa-
tion becomes a factor when estimating their incidence; both
JATD-1 and -16 did not have hand x-rays as adults, so we cannot
exclude their later development. Bilateral polydactyly was not
observed ( JATD-16 had unilateral postaxial polydactyly). Although
short stature with variable shortening of the limbs accompanied by
some bowing was frequently found in early childhood, in adoles-
cence and adulthood average height was reached in most cases.
Most patients had pelvic abnormalities with small ilia and typical
acetabular spurs. Strikingly, we observed a high variability in rib
shortening ranging from a slightly narrowed chest through to
severe narrowing leading to death in infancy, with a consequently
variable degree of respiratory problems (ﬁgure 2F–I and table 1).
These differences were observed between patients with different
DYNC2H1 mutations, and also between siblings with identical
DYNC2H1 genotypes, for example, in JATD-3, -18, -19 and
JATD-14 (Table 1, ﬁgure 2H,I). Some cases showed an improve-
ment of the disproportionate thorax with age (ﬁgure 2M–Q and
online supplementary ﬁgure S6).
Low incidence of renal or retinal disease in JATD patients
with DYNC2H1 mutations
Although there are several older patients (young adults or ado-
lescents) in our cohort, we identiﬁed renal and/or retinal abnor-
malities in only two affected individuals from families JATD-3
and -5. These were both generally more severe cases in whom
these features were detected at a very young age, in the second
month of life ( JATD-3) and in utero ( JATD-5). The ﬁnding that
neither kidney disease nor retinopathy occur frequently in JATD
patients with DYNC2H1 mutations in our cohort seems to con-
trast with clinical ﬁndings in JATD patients carrying mutations
in IFT140, where a high frequency of kidney disease and retin-
opathy has been found.9 12 However, as some of our
DYNC2H1 patients represent terminated fetuses and not all
patients have reached adulthood, we cannot exclude the possi-
bility that additional symptoms may develop in the future. Mild
liver disease was diagnosed in JATD-5 and -16, and bile duct
proliferation and portal tract ﬁbrosis in JATD-3 (table 2). This
overall lack of signiﬁcant renal, hepatic and pancreatic involve-
ment is consistent with previously reported JATD DYNC2H1
cases.13 There were other features in the cohort but these have
not been associated with JATD and are most likely unrelated,
including cardiac septum defects, oesophageal atresia, albinism,
unilateral ear malformation, bilateral toe syndactyly, patent
ductus arteriosus and testicular hydrocele (ﬁgure 2K,L).
IFT defects in ciliated ﬁbroblasts from patients with
DYNC2H1 mutations
Accumulations of anterograde transport proteins in ciliary tips are
typical cellular defects observed when retrograde IFT transport is
disrupted. We previously showed accumulations of the IFT-B pro-
teins IFT57 and IFT88 in ﬁbroblasts derived from patients with
skeletal ciliopathies due to mutations in IFT43, WDR35/IFT121
and WDR19/IFT144 that are all part of the IFT-A protein
complex.8 21 22 We also found this cellular phenotype in three of
the JATD patients with deﬁned DYNC2H1mutations in this study,
consistent with a disruption to IFT-A retrograde transport due to
DYNC2H1 deﬁciency. However, we saw different severity across
samples. Whereas accumulations of IFT-B proteins IFT57 and
IFT88 occurred in 50%–60% of ﬁbroblasts derived from patients
JATD-1 and -2, only 15% of cells were affected in JATD-3 (ﬁgure
3A–D, online supplementary ﬁgures S7 and S8). There was no
major effect on ciliary length compared with controls (patients
JATD-1, -2, -3 and -16, data not shown).
DISCUSSION
To our knowledge, this is the largest WES-related study per-
formed in JATD so far, comprising 71 patients from 57 families.
Our data indicate that DYNC2H1 is the most frequent overall
cause of JATD, accounting for 33% of the families screened in
this study. The high mutation frequency in JATD may be inﬂu-
enced by the size of the DYNC2H1 protein and its central role
in ciliary IFT. Since none of the DYNC2H1 patients have many
extra-skeletal ﬁndings, the frequency could also reﬂect a higher
survival rate of DYNC2H1 patients compared with those carry-
ing mutations in other JATD-related genes.
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We identiﬁed 34 DYNC2H1 mutations, 30 of which were
novel, and found these to occur more frequently in JATD
patients of Caucasian and Turkish origin than in patients of
African and Asian ethnic background. While DYNC2H1 muta-
tions account for 54% of the Caucasian cases we screened, and
38% of screened Turkish cases, we only detected one case of
biallelic DYNC2H1 mutations in other ethnicities (15 cases
screened, representing <10% of total cases, data not shown).
This might partly be due to European founder effects, at least
for p.D3015G, which we found in three Dutch families and
which was previously reported in a French family,13 and
perhaps also for two other mutations, that is, p.I1240T, which
was detected in German and French families that are described
in this study and previously,13 and p.E436*, which we identiﬁed
in two Dutch families here. One other mutation was also found
repetitively, p.R330C, albeit in families of different geographical
origin: a Turkish JATD family in this study and previously in a
SRPS type II patient of Haiti origin.24
Considering only the DYNC2H1 missense mutations, which
can indicate important functional clues about disease causing
mechanisms, the majority that we and others have described
tend to localise to the known, conserved functional domains of
DYNC2H1. This is similar to the mutation distribution deter-
mined in DNAH5, the heavy chain dynein gene mutated in
patients with primary ciliary dyskinesia, adding support to the
evidence for the DYNC2H1 variants being causal JATD alleles.
Remarkably, a large number of the DYNC2H1 missense muta-
tions localised to the region of the protein spanning
AAA3-AAA4; furthermore, p.D3015G, the most common
overall mutation is localised in close proximity within the
microtubule-binding stalk region. In contrast, we did not iden-
tify any mutations in the AAA1 domain, which is the main ATP
hydrolytic site of the DYNC2H1 motor domain and the
primary driver of HC dynein’s microtubular movement.61
Although AAA3 and AAA4 are very important for ATP binding,
their inﬂuence on ATP binding and microtubule sliding activities
Figure 2 Clinical features of DYNC2H1 patients. (A–E) Hallmarks of Jeune asphyxiating thoracic dystrophy ( JATD): (A, JATD-5; B, JATD-16) Small
thorax due to short ribs; (A, JATD-5, B, JATD-16, C, JATD-5, D, JATD-14) Small ilia with acetabular spurs; (C, JATD-5, D, JATD-14) Shortening of
femurs, accompanied by bowing in (D, JATD-14); (E) 3D reconstruction of CT images of patient JATD-4. (F–I) Severity of the rib shortening varies
between different patients from different families carrying DYNC2H1 mutations as well as between affected siblings: while patient JATD-5 presents
with extremely shortened ribs (F), patient JATD-18 (UCL62.2) is only mildly affected (G). (H, I) Patient JATD-14 (H, UCL80.1) is markably more
severely affected than his sister JATD-14 (I, UCL80.2). ( J–L) Additional features: ( J) scoliosis in JATD-2, (K) syndactyly in JATD-2, (L) ear
malformation in JATD-16. (M–Q) Thoracic narrowing becomes less pronounced with increasing patient age. (M) Shows patient JATD-16 at under
5 years; the same patient is shown a few years later in (N) at under 10 years. (O) Patient JATD-3 in his 20s, (P) patient JATD-2 in his late teens,
(Q) patient JATD-1 in his mid-20s these cases have less pronounced thoracic phenotypes compared to birth or infancy, as described in the text.
Note also that shortening of the upper limbs seems less severe when JATD patients reach adolescence.
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is less than AAA1, and they probably play a more regulatory
role.31 61 This importance could explain why currently no
AAA1 domain mutations were identiﬁed, as variants affecting
AAA1 function may be embryonic lethal in effect. A number of
missense variants also cluster in the N-terminal linker region
DHC-N2, which is thought to be the motile element of the
dynein heavy chain, essential for its movement along the
microtubules.62 63
These data collectively suggest that JATD DYNC2H1 missense
mutations would alter protein function, but may be ‘mild’ or
hypomorphic in their effect. In agreement, although seven puta-
tive ‘null’ nonsense, frameshift or deletion mutations were
Figure 3 Intraﬂagellar transport (IFT-B) accumulations in ciliary tips in Jeune asphyxiating thoracic dystrophy ( JATD) patient ﬁbroblasts. (A) In
contrast to wild type ﬁbroblasts (controls 1 and 2) in which IFT88 localises primarily to the ciliary base (and to a much lesser amount to the tip),
IFT88 concentrates distally in cilia in ﬁbroblasts derived from JATD-1, -2 and -3 family patients. Cells that were analysed in JATD-3 are derived from
affected individual II-4 (Table 1). Per condition at least 100 cells stained for IFT88, acetylated-α tubulin (marker for the ciliary axoneme) and
RPGRIP1L (marker for the ciliary base) as displayed in panel C were independently analysed by two blinded researchers. The control ﬁbroblast lines
were derived from individuals unrelated to our JATD patients. The graph shows that 64%, 59% and 14% of cells from patients from families 1, -2
and -3 demonstrate IFT88 concentrations in ciliary tips, whereas this effect is only observed in 3% and 2% of the cells from controls 1 and 2,
respectively. (B) Another IFT-B complex partner IFT57 also accumulates in ciliary tips of JATD ﬁbroblasts. While 53% and 50% of ciliated ﬁbroblasts
from JATD-1 and -2 patients demonstrate IFT57 accumulations in the ciliary tips, only 2% of the cells of the control display this cellular phenotype
(also see panel D). Cells were analysed as per (A). (C) Compared with controls, IFT88 accumulates in distal ends of cilia in ﬁbroblasts from JATD-1
and -2 patients. The images show a single cilium per patient or control in detail. Cells were stained with anti-IFT88 (green); antiacetylated α tubulin
(marker for the ciliary axoneme, cyan); and anti-RPGRIP1L (marker for the ciliary base, red). Whole-ﬁeld images displaying multiple cilia are
available in online supplementary ﬁgure S7. (D) Like IFT88, IFT57 collects distally in cilia in ﬁbroblasts from JATD-1 and -2 patients. Cells were
stained with anti-IFT57 (green); antiacetylated α tubulin (purple); and anti-RPGRIP1L (red). Whole-ﬁeld images displaying multiple cilia are available
in online supplementary ﬁgure S8.
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identiﬁed, no patients carried these in biallelic form, and none
were biallelic for any of the six splice site mutations either. This
presumed lack of a completely abolished protein function in sur-
viving patients has been previously reported for lethal ciliopathy
disorders including JATD.7 11 12 Experimental data using
knockout mouse models indeed suggest that JATD null alleles
are incompatible with mammalian development beyond
mid-gestation.42 64
Using the IFT-B proteins IFT57 and IFT88 as markers in
patient ﬁbroblasts, we showed that retrograde IFT transport is
disrupted as a result of loss of DYNC2H1 function, since these
anterograde transport proteins accumulate in the ciliary tips.
However, this effect was variable between JATD patient
samples, consistent with a previous report.8 Thus, in the diag-
nostic setting it is possible that immunoﬂuorescence studies may
be of help to narrow down which aspect of IFT is deﬁcient
before the molecular defect has been deﬁned, and second, they
could provide additional evidence that a candidate gene from
exome sequencing is likely the disease causing gene. However,
further studies are needed to evaluate the speciﬁcity of this test.
Currently we can only speculate based on the known biological
roles of these proteins that we would not also ﬁnd an accumula-
tion of IFT-B particles at ciliary tips in ﬁbroblasts of patients
with such defects. Furthermore, we have not performed any
comparative immunoﬂuorescence studies in ﬁbroblasts derived
from patients with mutations in genes encoding anterograde
IFT-B proteins such as IFT80, or proteins not known to be dir-
ectly involved in IFT such as NEK1, to determine any speciﬁc
differences in their IFT protein accumulations.
No major differences were observed in cilia number and
length in ﬁbroblasts from JATD patients, while ﬁbroblasts from
more severely affected patients with SRPS type III were previ-
ously reported to be signiﬁcantly shorter and displaying bulged
ciliary tips matching with defective IFT.26 Similar observations
of short, bulged cilia and conclusions that this results from deﬁ-
cient retrograde IFT have been reported in Dync2h1 knockout
mice.41 The different ﬁndings in mice compared with the
DYNC2H1 patients reported here may reﬂect a difference
between the mouse null allele and the putative hypomorphic
alleles revealed in the JATD patients. In line with this is the
ﬁnding that a hypomorphic Ift80 genetrap mouse which retains
partial protein expression has also been found to form cilia of
normal length.64 The reasons for the shorter cilia observed in
more severe SRPS cases caused by DYNC2H1 mutations are a
matter of speculation at this point, but could reﬂect a different
mutation mechanism for speciﬁc DNA variants that are more
deleterious to protein function, and/or may arise from an
increased mutational load, that is, additional mutations in other
ciliary genes inﬂuencing the phenotype in these patients.
A lack of extra-skeletal involvement was apparent for the
19 JATD families carrying DYNC2H1 mutations, apart from a
few cases with renal anomalies and/or mildly elevated liver
enzymes, or features that have not previously been described to
be associated with JATD. Most of these features such as digit 2/
3 syndactyly or unilateral ear malformation are likely to be unre-
lated as they occur quite frequently in the normal population,
and being ‘minor birth defects’ they might often not even been
reported; indeed, the 2/3 syndactyly in family JATD-2 was
present in family members unaffected by JATD. Conversely, it is
difﬁcult to reconcile how these features which include a rather
high frequency of mild cardiac septal defects occur as unrelated
features, since we have no explanation for their occurrence. The
lack of extra-skeletal involvement is consistent with the 13
DYNC2H1 patients previously reported, since renal, hepatic and
pancreatic abnormalities were seen in 5/13, but only cases with
severe SRPS disease, none with JATD.13 24–26 We also found
that patients can ‘grow out’ of their thoracic and short stature
phenotype as they get older, and that very often death due to
respiratory failure seems to be limited to the ﬁrst year of life,
which is consistent with previous reports.55 JATD patients carry-
ing IFT80 mutations also seem to exhibit a primarily thoracic
phenotype,10 but apart from this observation no major pheno-
type–genotype correlation has yet been published for JATD.
The nearly complete lack of retinal and renal disease in our
DYNC2H1 JATD patients is in striking contrast to an overall
high prevalence of childhood end stage renal disease and retin-
opathy that we and others have found in JATD and other
patients who carry biallelic IFT140 mutations.9 12
Although many ciliary and especially IFT genes are widely
expressed throughout the mammalian organism, and primary
cilia are present on nearly every cell throughout the human
body, ciliopathy phenotypes often seem to be restricted to
certain tissues.6 64 65 The reason for this remains unclear, but it
can be speculated that cell signalling pathways affected by muta-
tions in certain ciliary genes do not have an essential function in
every tissue; for example, hedgehog signalling may only cause a
visible phenotype in tissues most sensitive for pathway disturb-
ance, possibly in a time-dependent manner, such as during skel-
etal development. Another hypothesis could be that functionally
redundant proteins can compensate for each other’s loss in
certain tissues.66
Our ﬁndings have important implications for clinical diagnos-
tics, placing DYNC2H1 in a separate category from other genes
encoding IFT-related proteins, in which mutations are fre-
quently found to be associated with kidney disease and retinal
degeneration.6 14 65 However, a striking variability of thoracic
involvement between different DYNC2H1 patients and even
between siblings with identical DYNC2H1 genotype was
observed in this study. Thus, the rib length thoracic phenotype
in DYNC2H1-associated JATD and therefore survival chances in
infancy are difﬁcult to predict, even with the knowledge of the
underlying genotype. This presents a problem in a genetic coun-
selling setting, for example, in cases of prenatal diagnosis for
DYNC2H1 genotypes. At the moment, we can only speculate on
the causes of this variability which could be due to other
genetic factors such as modiﬁer genes/mutational load,11 42 67
or the involvement of epigenetic, environmental and/or stochas-
tic effects. In a similar vein, the p.R330C mutation seems to
cause SRPS type II24 as well as JATD without polydactyly, sug-
gesting the polydactyly phenotype does not solely depend on
this mutation but might be inﬂuenced by modiﬁer genes or epi-
genetic/non-genetic factors.
Most of the mutations we identiﬁed are private and they
occur across the entire DYNC2H1 gene. There is even a striking
lack of common alleles despite 5/19 families being consanguin-
eous, three being of common Turkish origin. This implies that
all 90 exons of DYNC2H1 would need to be screened in a clin-
ical genetics diagnosis context. Depending on the screening
method and the patient’s ethnic origin, a preliminary exclusion
of the ‘European’ mutations p.D3015G, p.R330C, p.I1240T
and p.E436* and a focus on the exons that encode the identiﬁed
functional protein domains would likely be desirable.
In summary, this large WES screen reveals DYNC2H1 muta-
tions as a frequent cause of JATD, affecting about a third of all
families. The mutation spectrum is enriched to DYNC2H1 func-
tional domains, with a few recurrent alleles, and this information
can help to target future genetic screening. The DYNC2H1-
related phenotype does not appear to arise in the context of
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biallelic null-effect mutations, and is predominantly thoracic
without extra-skeletal features. Immunostaining for cilia and IFT
components in patient ﬁbroblasts presents a potentially useful
readout for making a ‘skeletal ciliopathy’ diagnosis and can
provide a tool to functionally evaluate the signiﬁcance of muta-
tions in retrograde IFT genes. Together, these ﬁndings can help
to guide clinical diagnostic and genetic counselling decisions in
JATD.
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